




Operation: MicroPort Scientific Asia





1

2

3

4

5

6



Diagram 1: A vertical rectangular frame with a blue base. A dark blue rounded rectangle is positioned at the top. A circular inset at the bottom right shows a green, translucent, curved structure, possibly a medical device or anatomical part.

Diagram 2: A vertical rectangular frame with a blue base. A red rounded rectangle is positioned at the top. A circular inset at the bottom right shows a complex, multi-layered, fibrous structure, possibly a biological or material mesh.

Diagram 3: A vertical rectangular frame with a blue base. Two rounded rectangles are stacked vertically: a red one on top and a green one below it. A circular inset at the bottom right shows a white, textured, curved structure, possibly a medical device or anatomical part.

Diagram 4: A vertical rectangular frame with a blue base. Two rounded rectangles are stacked vertically: a red one on top and a green one below it. A circular inset at the bottom right shows a medical cart with a monitor and other equipment.

Diagram 5: A vertical rectangular frame with a blue base. Two rounded rectangles are stacked vertically: a red one on top and a green one below it. A circular inset at the bottom right shows a dark, textured, curved structure, possibly a medical device or anatomical part.

Diagram 6: A vertical rectangular frame with a blue base. A circular inset at the bottom right shows a white, mesh-like structure, possibly a biological or material mesh.

Diagram 7: A vertical rectangular frame with a blue base. A red rounded rectangle is positioned at the top. A circular inset at the bottom right shows a white, cylindrical container with a label, possibly a medical device or component.





- 
- 
- 
- 



1

2

3


4

5

6

Revenue


Non-Ortho  
Ortho



Group revenue up 15% excl. FX, 14% as reported


Operating Expenses

Non-Ortho  
Ortho




Percentage of sales improved by 4 percentage points

Gross Profit Margin



Gross Margin improved by 2 percentage points


Net Profit Attributable to Equity Shareholder



Net profit attributable to equity shareholder up by 33%




## Sales and Marketing Expenses




- 
- 

## Administrative Expenses






- 
- 

## Research and Develop. Expenses



- 
- 





1

2


3

4


5

6

## Revenue



## Revenue by Geographic Areas




## Highlights


- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 



Revenue




2017 SuperPath™ and Evolution™



- 
- 
- 




## Revenue of Cardiovascular Business





## Domestic Sales Growth by Products

Firehawk™ : 61% ↑ ; Firebird™ : 9% ↑



## Performance of DES in Domestic Market



## Highlights

- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 



## Promising Results of Target AC Clinical Trial


## New Countries & Distributors Development

## Highlights


- 
- 
- 
- 
- 
- 
- 
- 




## Revenue



## Product Pipeline



## Sales Growth by Products




## Highlights


- 
- 
- 
- 
- 




## Revenue



## Sales Growth by Products



## Pipeline -- Full range of solutions




## Highlights


- 
- 
- 
- 
- 
- 
- 
- 
- 
- 




## Revenue



## Sales Growth by Products




## EP Pipeline



## Highlights

- 
- 
- 
- 
- 
- 
- 
- 
- 





1


2

3

4

5





Horizontal dashed lines for writing, aligned with the colored bars on the left.

1


2

3

4

5

6





[Redacted text]

[Redacted text]

[Redacted text]



[Redacted text]

[Redacted text]


[Redacted text]



[Redacted text]

[Redacted text]

[Redacted text]





[Redacted text]





- 
- 
- 
- 



1

2

3

4

5

6

| (USD '000)                                        | 2017           | 2016           | Flux %       |
|---------------------------------------------------|----------------|----------------|--------------|
| <b>Revenue</b>                                    | <b>444,190</b> | <b>389,921</b> | <b>14.0%</b> |
| Cost of sales                                     | (125,793)      | (118,243)      | 6.4%         |
| <b>Gross profit</b>                               | <b>318,397</b> | <b>271,678</b> | <b>17.2%</b> |
| Other revenue & net gain/(loss)                   | (2,540)        | 20,677         | -112.3%      |
| Research and development costs                    | (58,150)       | (51,897)       | 12.0%        |
| Distribution costs                                | (137,766)      | (128,464)      | 7.2%         |
| Administrative expenses                           | (66,804)       | (64,245)       | 4.0%         |
| Other operating costs                             | (5,276)        | (1,818)        | 190.2%       |
| <b>Operating Profit</b>                           | <b>47,861</b>  | <b>45,931</b>  | <b>4.2%</b>  |
| Finance costs                                     | (13,489)       | (16,704)       | 19.2%        |
| Gain on disposal of subsidiaries                  | 6,531          |                | N/A          |
| Share of losses of JV and associates              | (10,535)       | (3,941)        | 167.3%       |
| <b>Profit before taxation</b>                     | <b>30,368</b>  | <b>25,286</b>  | <b>20.1%</b> |
| Income tax                                        | (13,417)       | (10,217)       | 31.3%        |
| <b>Net profit</b>                                 | <b>16,951</b>  | <b>15,069</b>  | <b>12.5%</b> |
| <b>Profit attributable to equity shareholders</b> | <b>18,823</b>  | <b>14,141</b>  | <b>33.1%</b> |





